Melanoma Clinical Trials

20 trials recruiting in Canada.

Cancer

Recruiting Drug Device Behavioral Older adults Healthy volunteers

15 trials

Comparing fianlimab with relatlimab+nivolumab for melanoma

Explore this study →

There are 2 groups in this study. Group A receives fianlimab and cemiplimab. Group B, the comparison group, receives relatlimab+nivolumab.

Sites in Toronto, Calgary and 4 more cities

Phase 3
2 groups
Sites in Calgary, Edmonton and 4 more cities
Recruiting

Official title: A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

Melanoma · Regeneron Pharmaceuticals

Comparing 3 approaches for melanoma

Explore this study →

There are 3 groups in this study. Group A receives dabrafenib. Group B receives trametinib. Group C receives dabrafenib and trametinib.

One site, in Toronto

Phase 4
3 groups
One site, in Toronto
Recruiting

Official title: Dabrafenib and/or Trametinib Rollover Study

Melanoma · Novartis Pharmaceuticals

Comparing IMA203 with nivolumab plus relatlimab for cutaneous malignant melanoma

Explore this study →

There are 2 groups in this study. Group A receives IMA203. Group B, the comparison group, receives one or more of: nivolumab plus relatlimab, lifileucel, nivolumab, pembrolizumab, ipilimumab, Dacarbazine, temozolomide, paclitaxel, paclitaxel plus carboplatin and Albumin-Bound Paclitaxel.

Sites in Edmonton, Montreal and 2 more cities

Phase 3
2 groups
Sites in Edmonton, Vancouver and 2 more cities
Recruiting

Official title: SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Melanoma, Cutaneous Malignant · Immatics US, Inc.

Get matched to the best-fit trials

Answer a few questions and we'll find the closest matches for melanoma.

Testing Nicotinamide against a placebo for non-melanoma skin cancer

Explore this study →

There are 2 groups in this study. Group A receives Nicotinamide. Group B, the placebo group, receives Placebo.

Sites in Toronto, Vancouver and 3 more cities

Phase 3
2 groups
Sites in Calgary, Edmonton and 3 more cities
Recruiting

Official title: Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial

Non-melanoma Skin Cancer · Women's College Hospital

Comparing Opdualag with Nivolumab for cutaneous melanoma

Explore this study →

There are 2 groups in this study. Group A receives Opdualag, together with one or more of: Nivolumab. Group B, the comparison group, receives Nivolumab.

One site, in Toronto

Phase 2
2 groups
One site, in Toronto
Recruiting

Official title: Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma

Cutaneous Melanoma · University Health Network, Toronto

Comparing 3 approaches for advanced melanoma

Explore this study →

There are 3 groups in this study. Group A, the comparison group, receives Pembrolizumab (KEYTRUDA® ). Groups B and C receive one or more of: EIK1001 and Pembrolizumab (KEYTRUDA® ).

One site, in Toronto

Phase 2
3 groups
One site, in Toronto
Recruiting

Official title: Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

Advanced Melanoma · Eikon Therapeutics

Testing LND101 for melanoma

Explore this study →

There are 2 groups in this study. Group A, the comparison group, receives Standard of Care Immune Checkpoint Blockade. Group B receives LND101, together with one or more of: Standard of Care Immune Checkpoint Blockade.

Sites in Montreal, Toronto and 10 more cities

Phase 2
2 groups
Sites in Abbotsford British Columbia, Surrey and 10 more cities
Recruiting

Official title: LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma

Melanoma · Canadian Cancer Trials Group

Testing Darovasertib with Crizotinib (Xalkori) for uveal melanoma

Explore this study →

There are 2 groups in this study. Group A receives one or more of: Darovasertib and Crizotinib (Xalkori). Group B receives no study treatment and is followed for comparison.

Sites in Montréal and Toronto

Phase 3
2 groups
One site, in Toronto
Recruiting

Official title: Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma

Uveal Melanoma · IDEAYA Biosciences

Comparing Intermittent PD-1 inhibitor therapy with Continuous PD-1 inhibitor therapy for unresectable/metastatic melanoma

Explore this study →

There are 2 groups in this study. Group A, the comparison group, receives Intermittent PD-1 inhibitor therapy. Group B, the comparison group, receives Continuous PD-1 inhibitor therapy.

Sites in Toronto, Barrie and 16 more cities

Phase 3
2 groups
Sites in Edmonton, Surrey and 16 more cities
Recruiting

Official title: Duration of Anti-PD-1 Therapy in Metastatic Melanoma

Unresectable/Metastatic Melanoma · Canadian Cancer Trials Group

Comparing 3 approaches for advanced melanoma

Explore this study →

There are 3 groups in this study. Group A receives Tebentafusp. Group B receives Tebentafusp with Pembrolizumab. Group C receives Investigators Choice.

Sites in Montreal, Toronto and 1 more city

Phase 3
3 groups
Sites in Vancouver, Toronto and 1 more city
Recruiting

Official title: Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Advanced Melanoma · Immunocore Ltd

Testing Definity with Sonalleve Focused Ultrasound Device for melanoma

Explore this study →

Everyone in this study is in one group, which receives one or more of: Definity and Sonalleve Focused Ultrasound Device.

One site, in Toronto

Phase 1
1 group
One site, in Toronto
Recruiting

Official title: MRI-Guided Focused Ultrasound Radiosensitization for Patients With Malignant Melanoma and Non Melanoma Skin Cancer

Melanoma · Sunnybrook Health Sciences Centre

Comparing 3 approaches for advanced melanoma

Explore this study →

There are 3 groups in this study. Groups A and B receive Brenetafusp and Nivolumab. Group C, the comparison group, receives Nivolumab and Nivolumab + Relatlimab.

Sites in Edmonton and Toronto

Phase 3
3 groups
Sites in Toronto and Edmonton
Recruiting

Official title: IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

Advanced Melanoma · Immunocore Ltd

Comparing Stereotactic Body Radiotherapy with Immunotherapy alone for melanoma metastatic

Explore this study →

There are 2 groups in this study. Group A is listed in the registry as “Arm A: Concurrent stereotactic body radiotherapy + Immune checkpoint inhibitor(s)”. Group B, the comparison group, receives Immunotherapy alone.

One site, in Toronto

Phase 2
2 groups
One site, in Toronto
Recruiting

Official title: Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma

Melanoma Metastatic · Melanoma Institute Australia

Comparing Darovasertib with Primary Local Therapy for uveal melanoma

Explore this study →

There are 2 groups in this study. Group A receives Darovasertib. Group B, the comparison group, receives Primary Local Therapy.

Sites in Edmonton and Toronto

Phase 3
2 groups
Sites in Edmonton and Toronto
Recruiting

Official title: Neoadjuvant Darovasertib in Primary Uveal Melanoma

Uveal Melanoma · IDEAYA Biosciences

Comparing 8 approaches for metastatic uveal melanoma

Explore this study →

There are 8 groups in this study. Groups A and B receive IDE196. Groups C and D receive Binimetinib, together with one or more of: IDE196. Groups E, F, G and H receive Crizotinib, together with one or more of: IDE196.

One site, in Toronto

Phase 1
8 groups
One site, in Toronto
Recruiting

Official title: Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Metastatic Uveal Melanoma · IDEAYA Biosciences

Looking for the closest fit?

Get matched →

Ask someone to look with you

Whether or not the results above are what you were looking for, someone at Concord can search with you.

Get notified when a matching trial opens

We'll watch for Melanoma trials near you.

← Back to all conditions

Concord provides information support only. Trial listings come from public registries; eligibility is always determined by the trial site and your care team.